MedPath

The Effects of Nanocurcumin on Serum Oxidative Stress,Inflammation,Adiponectin and NF-kB in Blood Mononuclear Cells in Metabolic Syndrome Patients (Nuclear Factor-κB)

Not Applicable
Conditions
Metabolic Syndrome
Interventions
Dietary Supplement: nanomicielle curcumin
Dietary Supplement: placebo
Registration Number
NCT03514667
Lead Sponsor
National Nutrition and Food Technology Institute
Brief Summary

Metabolic syndrome is a public health challenge that includes a range of conditions including abdominal obesity, dyslipidemia, hyperglycemia, and hypertension. The syndrome is associated with an increase in the risk of Cardiovascular disease and death. Curcumin is a very active compound obtained from turmeric root. Curcumin has antioxidant and anti-inflammatory effects, and is also involved in the regulation of several signaling pathways. Since curcumin powder has low bioavailability, fast metabolism and low absorption, nanomicielle curcumin will be used in this study. Therefore, this study is planned to determine the effects of supplementation of nanomicielle curcumin on oxidative stress, systemic inflammation, adiponectin in serum and NF-kB in peripheral blood mononuclear cells in patients with metabolic syndrome.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
50
Inclusion Criteria
  • 25<body mass index >40
  • waist circumference >102 cm in men or >88 cm in women
  • Fasting blood glucose >100 mg/dL
  • Triglycerides (TG) > 150 mg/dL
  • High density lipoprotein cholesterol (HDL-C) <50 in women or <40 in men
  • Systolic blood pressure (SBP) >130 mmHg and diastolic blood pressure (DBP) >85mmHg
Exclusion Criteria
  • insulin administration for diabetes control
  • hypo- or hyperthyroidism,
  • renal failure or other chronic diseases
  • pregnancy and breastfeeding
  • taking weight loss supplements and obeying unusual weight loss plans

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
intervention groupnanomicielle curcumin80 mg nanomicielle curcumin capsules once a day for 12 weeks
control groupplaceboplacebo capsules once a day for 12 weeks
Primary Outcome Measures
NameTimeMethod
Serum C-reactive protein (CRP)12weeks
Serum Adiponectin12weeks
Serum Total antioxidant capacity (TAC)12 weeks
Serum Malondialdehyde (MDA)12weeks
Serum curcumin12 weeks
NF-kB(p65) transcription in PBMC12weeks
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Golbon Sohrab

🇮🇷

Tehran, National Nutrition And Food Technology Research Institute, Iran, Islamic Republic of

© Copyright 2025. All Rights Reserved by MedPath